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Cancer drug resistance and poor selectivity towards cancer cells demand the constant search for new 
therapeutics. PI3K-Akt-mTOR and RAS-MAPK-ERK signaling pathways are key mechanisms involved 
in cell survival, proliferation, differentiation, and metabolism and their deregulation in cancer can pro-
mote development of therapy resistance. We investigated the effects of targeted inhibitors (wortmannin, 
GSK690693, AZD2014 and tipifarnib) towards these two pathways on early zebrafish and sea urchin 
development to assess their toxicity in normal, fast proliferating cells. PI3K inhibitor wortmannin and 
RAS inhibitor tipifarnib displayed highest toxicity while GSK690693, a pan-Akt kinase inhibitor, exhib-
ited a less significant impact on embryo survival and development. Moreover, inhibition of the upstream 
part of the PI3K-Akt-mTOR pathway (wortmannin/GSK690693 co-treatment) produced a synergistic 
effect and impacted zebrafish embryo survival and development at much lower concentrations. Dual 
mTORC1/mTORC2 inhibitor AZD2014 showed no considerable effects on embryonic cells of zebrafish 
in concentrations substantially toxic in cancer cells. AZD2014 also caused the least prominent effects on 
sea urchin embryo development compared to other inhibitors. Significant toxicity of AZD2014 in human 
cancer cells, its capacity to sensitize resistant cancers, lower antiproliferative activity against human 
normal cell lines and fast proliferating embryonic cells could make this agent a promising candidate for 
anticancer therapy.
Keywords: PI3K-Akt-mTOR signaling pathway – RAS-MAPK-ERK signaling pathway – zebrafish 
(Danio rerio) – sea urchin (Arbacia lixula) – AZD2014
INTRODUCTION
One of the main obstacles for successful cancer treatment is the development of 
resistance to chemotherapy. PI3K-Akt-mTOR and RAS-MAPK-ERK signaling path-
ways are among the main cellular mechanisms involved in the regulation of cell 
survival, proliferation, differentiation, and metabolism [24, 26]. Deregulation of these 
pathways may result in resistance to therapy which is common for numerous cancer 
types [23, 24]. The role of PI3K-Akt-mTOR and RAS-MAPK-ERK pathway inhibi-
tion in chemosensitization of resistant cancers has been extensively studied and vari-
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ous inhibitors of these pathways were investigated as potential agents to overcome 
the problem of multidrug resistance [1, 27, 29]. Additional problem in cancer therapy 
is its nondiscriminatory nature between normal and cancer cells. Many agents do not 
spare normal cells and may have substantial cytotoxic effects on normal tissue. Some 
cell types in bone marrow or gastrointestinal lining have a rapid turnover, and can be 
more susceptible to drug toxicity. For instance, the toxic effect in bone marrow cells 
can lead to development of anemia and neutropenia, while toxicity in the gastrointes-
tinal tract can result in colitis [5].
Zebrafish represents an excellent model to study the toxicity of different substanc-
es [12]. As an in vivo system for toxicology, zebrafish has many advantages including 
rapid and ex utero development, transparent and small embryos in early stages, high 
fecundity enabling high-throughput screening and cost effectiveness [4]. Zebrafish 
genome has approximately 70% of human genes and about 82% of potential human 
disease related genes have at least one zebrafish orthologue [16]. Additionally, the 
studies of known toxic substances on zebrafish revealed 63–100% of predictability 
which makes zebrafish a good model to study toxic effects [11, 14, 17]. 
The sea urchin embryo has long been used as a model for developmental studies 
and drug toxicity testing. Multiple factors such as inexpensive growth procedure, 
simple artificial spawning and fertilization, rapid synchronous development, optical 
transparency of embryos and well understood embryogenesis, make this organism 
suitable for conducting a variety of biological tests. Other advantages that make sea 
urchin embryo particularly convenient for toxicity studies include high permeability 
of eggs and embryos to chemicals, rapid cell divisions, observable markers of viabil-
ity and biochemical similarity to vertebrates and mammals [28]. As a result, various 
antiproliferative agents have been tested for their effects on the sea urchin embryo 
development [20, 30].
The aim of this study was to assess the effect of different signaling pathway 
inhibitors in vertebrate and invertebrate embryonic models. For this reason, we fol-
lowed early zebrafish (Danio rerio) and sea urchin (Arbacia lixula) development in 
order to assess inhibitors’ toxicity on normal, fast proliferating cells. We have inves-
tigated four inhibitors of key components in PI3K-Akt-mTOR and RAS-MAPK-ERK 
pathways: wortmannin – specific inhibitor of PI3K; GSK690693 – ATP-competitive 
Akt kinase inhibitor, AZD2014 – dual mTORC1 and mTORC2 inhibitor and tipi-
farnib – RAS inhibitor.
MATERIALS AND METHODS
Drugs
Wortmannin, GSK690693, AZD2014, and tipifarnib were kindly provided by 
Selleckchem (Houston, TX, USA). All drugs were diluted in DMSO and 10 mM 
aliquots were stored at –20 °C. Before treatment, all drugs were freshly diluted in 
water.
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Zebrafish husbandry
Tübingen wild type zebrafish (Danio rerio) were housed at 28 ± 1 °C on a 12:12 
light–dark photoperiod, according to good laboratory practice. Adults and embryos 
were maintained in water containing 5.5 mg KCl, 294 mg CaCl2 ∙ 2H2O, 123 mg 
MgSO4 ∙ 7H2O and 63 mg NaHCO3 per L. Zebrafish were spawned every seven days. 
Spawn was discarded if more than 10% of eggs were unfertilized. 
Zebrafish treatments
Experiments were performed in 24-well plates. Twelve embryos were placed in each 
well in 750 µl of the appropriate solution. Three different concentrations of each 
inhibitor were tested per each experiment (wortmannin: 0.5 µM, 1 µM, 2.5 µM; 
GSK690693: 0.5 µM, 1 µM, 5 µM; AZD2014: 0.1 µM, 0.5 µM, 1 µM, tipifarnib: 
1 µM, 5 µM, 10 µM). Two different combinations of inhibitors were also tested: 
1 µM wortmannin + 1 µM GSK690693 and 1 µM GSK690693 + 1 µM AZD2014. 
Treatments started 2, 6 or 24 hours post fertilization (hpf) for single treatments and 
6 hpf for combination treatments. Treatments for all concentrations were repeated 
three times using embryos obtained from three independent spawns. All experiments 
contained untreated and 0.01% dimethyl sulfoxide (DMSO) treated groups, as con-
trols. 
Developmental toxicity screen
The embryos were observed under the stereomicroscope PXS- IV (Optica Co. Ltd, 
Thailand) at 40x magnification and imaged with camera CKX41 (Olympus, Japan). 
Embryo survival was observed at 24, 48 and 72 hpf. Embryos that were coagulated 
or where no heartbeat could be detected were considered dead. Embryo hatching rate 
was observed at 48 and 72 hpf, as hatching normally occurs between 48 and 72 hpf. 
Developmental malformations (head malformation, eye malformation, eye pigmenta-
tion, otoliths malformation, chorda malformation, tail malformation, scoliosis, yolk 
deformation/edema, heart malformation, pericardial edema, tail circulation, growth 
retardation, body pigmentation) were observed at 72 hpf after hatching.
Handling of sea urchin gametes
Adult Arbacia lixula sea urchins were collected by scuba in the Adriatic Sea and were 
immediately transported (maximum 1 h transportation time) to the Institute for 
Marine Biology (Kotor, Montenegro). They were subsequently kept in circulating and 
filtered artificial sea water (ASW) (27.6 g/l NaCl, 0.67 g/l KCl, 1.36 g/l CaCl2 × 
2H2O, 6.29 g/l MgSO4 × 7H2O, 4.66 g/l MgCl2 × 6H2O, 0.18 g/l NaHCO3, pH 7.5) at 
398 Tamara Babic et al.
Acta Biologica Hungarica 69, 2018
21 °C. Eggs or sperm were obtained by injecting the animals with 1 ml of 0.55 M 
KCl, and fertilization of the eggs was carried out using the sperm of one male with 
eggs acquired from 2 to 4 females. 
Sea urchin embryo treatments
Approximately 100 fertilized sea urchin eggs were placed in 1 ml of ASW per well 
in 6-well plates. Two different concentrations were assessed for each inhibitor: 
AZD2014 (0.25 and 0.5 μM), GSK690693 (2.5 and 5 μM) and tipifarnib (5 and 10 
μM). Treatment was performed after visible assembly of the sea urchin fertilization 
membrane, which occurs approximately 20 min after sperm fusion with the egg. After 
24 h, control and treated embryos were examined under Leica DMI4000 B micro-
scope (Leica Microsystems GmbH, Germany) at 5× magnification. A minimum of 30 
embryos were observed for each condition. The results are presented as percentage of 
nonviable and viable embryos in different developmental stages (undeveloped embry-
os, swimming blastula and late gastrula) in control and treated groups.
Statistical analysis
All data are shown as mean ± SEM. Differences between control and single treatments 
were assessed using one-way analysis of variance (ANOVA) followed by Dunette’s 
test. In combined treatments, the results were analyzed with t-test. The minimum 
significant level was set at p ≤ 0.05. Statistical analyses were performed using 
GraphPad Prism 5 or 6. 
RESULTS
Wortmannin causes decreased embryo survival and  
morphological malformations
There were no significant differences between untreated embryos and embryos incu-
bated in 0.01% DMSO. Untreated embryos did not show mortality or developmental 
malformations at any time of observation. Hatching rate of untreated embryos was 
around 44% at 48 hpf and 100% at 72 hpf. 
Wortmannin induced dose-dependent decreased survival rate in embryos treated 2 
and 6 hpf when compared to the control group at 72 hpf. However, only 2.5 µM treat-
ment applied at 2 hpf produced a statistically significant result (58%, Fig. 1A). 
Wortmannin also induced a dose- dependent hatching rate decrease in embryos 
treated 2 and 6 hpf when compared to the control group at 48 hpf (Fig. 1B). Still, only 
2.5 µM treatment applied at 2 hpf caused statistically significant result by completely 
blocking the hatching. 
Targeted therapeutics in zebrafish and sea urchin 399
Table 1
Embryo malformations induced by wortmannin
Malformations
2 hpf 6 hpf 24 hpf
0.5 µM 1 µM 2.5 µM 0.5 µM 1 µM 2.5 µM 0.5 µM 1 µM 2.5 µM
Decreased body 
length np 100% 100% np 100% 100% np 100% 100%
Voluminous yolk sac np 100% np np 100% np np 100% np
Yolk sac edema np np 100% np np 100% np np 100%
Pericardial edema np np 100% np np 100% np 52% 100%
Scoliosis np np 22% np np np np np np
*np – not present.
Fig. 1. Wortmannin affects survival and development in zebrafish embryos. A) Survival rate of 72 hpf zebrafish 
embryos treated with wortmannin at 2, 6 or 24 hpf. B) Hatching rate of 48 hpf zebrafish embryos treated with wort-
mannin at 2, 6 or 24 hpf. C) Representative images of morphological malformations in 72 hpf zebrafish embryos 
treated with wortmannin at 2, 6 or 24 hpf
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Wortmannin treatment induced multiple malformations in zebrafish embryos. The 
observed effects were more prominent in earlier treatment starting points and were 
concentration dependent (Table 1, Fig. 1C). Treatment with 1 µM wortmannin 
decreased body length and produced voluminous yolk sac in comparison to the con-
trol group. Furthermore, embryos treated with 1 µM wortmannin 24 hpf had pericar-
dial edema. Treatment with 2.5 µM wortmannin caused shorter body length com-
pared to controls and 0.5 µM and 1 µM treatments, as well as yolk sac edema and 
pericardial edema. Additionally, embryos treated with 2.5 µM wortmannin 2 hpf 
showed scoliosis (Table 1, Fig. 1C).
GSK690693 and AZD2014 do not influence zebrafish embryo survival 
and development
The zebrafish embryos were also treated at different time points with increasing con-
centrations of GSK690693. GSK690693 did not affect survival or embryonic devel-
opment, but decreased hatching of the embryos observed at 48 hpf in comparison to 
Fig. 2. GSK690693 affects hatching but not development in zebrafish embryos. A) Hatching rate of 48 
hpf zebrafish embryos treated with GSK690693 at 2, 6 or 24 hpf. B) Representative images of 72 hpf 
zebrafish embryos treated with GSK690693 at 2, 6 or 24 hpf
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control groups. All concentrations of GSK690693 decreased hatching rate of embry-
os at all treatment starting time points (Fig. 2A). No malformations during the devel-
opment were observed in any of the GSK690693 treatments (Fig. 2B). Treatment 
with increasing concentrations of AZD2014 caused dose-dependent decrease in 
hatching rate at all treatment starting time points (Fig. 3A). No differences in sur-
vival of AZD2014 treated embryos compared to controls, or any malformations dur-
ing the development were observed (Fig. 3B). 
Co-treatments with PI3K-Akt-mTOR pathway inhibitors cause decrease 
in zebrafish embryo survival and multiple malformations
Subsequently, the embryos were exposed to combined treatment with wortmannin 
and GSK690693 or GSK690693 and AZD2014. Combined treatment with 1 µM 
wortmannin and 1 µM GSK690693 significantly decreased embryo survival rate 
Fig. 3. AZD2014 affects hatching but not development in zebrafish embryos. A) Hatching rate of 48 hpf 
zebrafish embryos treated with AZD2014 at 2, 6 or 24 hpf. B) Representative images of 72 hpf zebrafish 
embryos treated with AZD2014 at 2, 6 or 24 hpf
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Fig. 4. PI3K-Akt-mTOR pathway inhibitors co-treatments affect survival and development in zebrafish 
embryos. A) Survival rate of 24 hpf zebrafish embryos treated with wortmannin and GSK690693 combi-
nation at 6 hpf. B) Representative images of morphological malformations in 72 hpf zebrafish embryos 
treated with wortmannin and GSK690693 combination at 6 hpf. C) Representative images of morpho-
logical malformations in 72 hpf zebrafish embryos treated with GSK690693 and AZD2014 combination 
at 6 hpf
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(86%) observed at 24 hpf (Fig. 4A). Additionally, all embryos had decreased body 
length, while 79% of embryos had hemagglutination and 70% had malformation of 
the tail (Fig. 4B). 
Combined treatment with 1 µM GSK690693 and 1 µM AZD2014 inhibitors did 
not alter survival or hatching rate, however decreased body length of all embryos was 
observed. Additionally, this combined treatment caused voluminous yolk sac in 65% 
of treated embryos (Fig. 4C).
Tipifarnib causes multiple morphological malformations  
in zebrafish embryos
Tipifarnib treatment did not affect the embryo survival or hatching rate, however, 
multiple malformations of the embryos were observed all treatment starting 
time points (Fig. 5). The most prominent malformation was decrease in body length 
(Table 2). Yolk sac edema and pericardial edema were also observed.
The effects of PI3K-Akt-mTOR and RAS-MAPK-ERK pathway inhibitors 
on early sea urchin development
Fertilized sea urchin eggs were treated with 0.25 µM or 0.5 µM AZD2014 20 min 
after fertilization and the effect on the embryo survival and development was 
observed after 24 h (Fig. 6). Treatment with 0.25 µM produced 8% late gastrula 
embryos while 52% of embryos were dead after 24 h. The mobility of live embryos 
was reduced compared to the untreated group. After treatment with 0.5 µM AZD2014 
2% of embryos reached the late gastrula stage, 3% of embryos were arrested as 
deformed stationary blastulas (compared to 23% swimming blastulas in the control 
group) and 74% of embryos became nonviable. 
After 24 h treatment with 2.5 µM GSK690693 there were no late gastrulas and 4% 
embryos were arrested at the swimming blastula stage which retained mobility 
despite their altered morphology (Fig. 6). However, the majority of embryos remained 
undeveloped (57% in treated group compared to 15% in control) and 39% of 
embryos were dead. Treatment with 5 µM GSK690693 produced 63% undeveloped 
Table 2
Embryo malformations induced by tipifarnib
Malformations
2 hpf 6 hpf 24 hpf
1 µM 5 µM 10 µM 1 µM 5 µM 10 µM 1 µM 5 µM 10 µM
Decreased body length np 100% 100% np 100% 100% np np 100%
Voluminous yolk sac np 65% 100% np np 100% np np 82%
Pericardial edema np np 27% np np 36% np np np
*np – not present.
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embryos, 3% of swimming blastulas with significantly reduced mobility and 32% of 
dead embryos. The morphology of undeveloped embryos was significantly altered.
After the fertilization membrane became visible, sea urchin embryos were also 
treated with 5 µM or 10 µM tipifarnib (Fig. 6). The impact on embryo viability and 
developmental delay was observed after 24 h. Treatment with 5 µM tipifarnib arrest-
ed the embryos at various stages of development. Compared to control where 62% of 
embryos reached the late gastrula, none of the embryos treated with 5 µM tipifarnib 
were observed at this developmental stage. Furthermore, the treatment had a high 
impact on viability since 69% of embryos became nonviable after 24 h while no dead 
embryos were found in the control group. Application of higher concentration of 
tipifarnib (10 µM) produced similar results.
DISCUSSION
One of the currently most investigated problems in cancer treatment is the develop-
ment of non-toxic therapies to normal cells,mean while retaining the ability to suc-
cessfully inhibit tumor growth. Novel adjuvant therapies are being developed to 
increase the effectiveness of existing drugs.
This study was addressed to the time- and dose-dependent responses of zebrafish 
and dose-dependent responses of sea urchin embryos on chemical inhibitors of 
PI3K-Akt-mTOR and RAS-MAPK-ERK signaling pathways components. The toxic 
effects of these inhibitors alone or in combinations were investigated in vivo in 
zebrafish and sea urchin embryos that served as models for fast proliferating, but not 
transformed cells. To the best of our knowledge, this is the first report investigating 
the effects of GSK690693, AZD2014 and tipifarnib on zebrafish and sea urchin 
embryo models.
We have selected several treatment time points for zebrafish embryos: blastula (2 
hpf), gastrula (6 hpf) and pharyngula (24 hpf) stages, as numerous differences in 
speed and pattern of cell proliferation during these developmental stages have previ-
ously been reported [25]. The most prominent effects on the embryo survival and 
development were present in treatments started at the earliest time point in all studied 
inhibitors. Inhibitor concentrations selected for treatments were previously shown to 
have a significant effect on proliferation, and trigger autophagy and apoptosis in nor-
mal and cancer cell lines [10]. It should be taken into account that, compared to 
zebrafish embryos, sea urchin embryos were found to be generally more sensitive to 
a number of chemicals and drugs [6], which is in line with our observations.
Wortmannin, a PI3K inhibitor, has been previously shown to exhibit high toxicity 
during fertilization and development of sea urchin [9]. It has been reported that wort-
mannin treatment disrupts the mitotic spindle formation and subsequently the first 
cell division of the fertilized egg. Similarly, in our model wortmannin treatment 
resulted only in nonviable disintegrated embryos after 24 hours and was therefore 
excluded from our sea urchin experiments. In zebrafish embryos, treatment with 2.5 
µM wortmannin at the blastula stage decreased embryo survival and hatching rate. 
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Additionally, several morphological malformations have also been observed. It has 
been previously shown that wortmannin exhibited high cardiotoxicity in zebrafish 
embryos although independently of PI3K inhibition [32]. It has also been reported 
that wortmannin affected cancer cell growth at micromolar concentrations (IC50 = 30 
µM) and improved the activity of doxorubicin and cisplatin in thyroid carcinoma cell 
lines [27]. Our observation, that wortmannin exhibits substantial effects on zebrafish 
survival and morphology in much lower concentrations compared to human cancer 
cell lines (2.5 µM), does not favor this inhibitor as an anticancer agent as it affects 
normal as well as cancer cells.
GSK690693 is a small molecule that acts as ATP-competitive inhibitor of Akt1, 
Akt2 and Akt3. This agent affected sea urchin fertilization and development, but its 
effects on zebrafish development were negligible. It did not impact zebrafish embryo 
survival, but caused delayed hatching that could not be attributed to either the time of 
treatment or applied concentration. The process of hatching is complex and influ-
enced by many physical and chemical factors. In zebrafish, hatching glands produce 
proteolytic enzyme that weakens chorion and facilitates hatching [8]. Also, oxygena-
tion of water and other physic-chemical water properties could affect hatching [15]. 
Presence of pollutants in water has been shown to influence hatching rate [31]. As the 
differences between treated animals and controls in hatching rate were not present 
after 72 hpf (all the surviving embryos were hatched in all groups), the detailed 
analysis of hatching was not performed. GSK690693 has been found to be active in 
vitro against many cell types, inhibiting their growth in micro molar range (IC50 val-
ues from 8 to 25 µM) [7, 21, 27]. However, in vivo studies on xenograft models, 
GSK690693 exhibited effects not very promising to further promote it as anticancer 
agent [2, 7].
AZD2014 is an ATP-competitive mTOR kinase inhibitor, affecting both mTORC1 
and mTORC2, currently in phase II clinical trials [13]. In our experimental setup, 
AZD2014 treatment did not affect embryo survival, but resulted in time- and dose- 
dependent delayed hatching at 48 hpf, compared to controls, but this difference disap-
peared after 72 hpf. AZD2014 treatment leads to body length shortening in some 
embryos only at highest, 1µM, concentration.
None of the AZD2014 treated embryos showed any other morphological malfor-
mations. Although sea urchin embryo viability was low and substantial developmen-
tal delay was observed in all treatments, only treatment with AZD2014 managed to 
produce a noteworthy number of embryos that reached the swimming blastula and 
late gastrula stage. It has been shown that AZD2014 sensitized oral squamous cancer 
cells and glioblastoma stem-like cells to treatment with ionizing radiation [19, 33]. 
In vitro, AZD2014 showed highest growth arrest potential in thyroid and colorectal 
cancer cells, acting in nanomolar range (IC50 values from 0.15 to 0.21 µM), compared 
to the other inhibitors used in this study [18, 27]. Additionally, it was demonstrated 
that it most effectively lowered IC50 values for classic chemotherapeutics doxorubicin 
and paclitaxel [27]. AZD2014 was also shown to inhibit proliferation and induce 
apoptosis in liver cancer cells [22]. In our previous work, we have found that 
AZD2014 induced autophagy in concentrations that had no effect on development, 
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and prevented cisplatin-induced apoptosis in zebrafish embryos. Autophagy modula-
tion with AZD2014 triggered the cellular response to anticancer drugs more effec-
tively in NCI-H460 (human non-small cell lung carcinoma) and zebrafish embryonic 
models compared to human normal HaCaT cells suggesting that these modulators are 
selective towards rapidly proliferating cells [10]. Taken together with these findings, 
our results further promote AZD2014 as a promising anticancer agent. Of all the 
inhibitors tested, AZD2014 had the least influence on the normal embryonic develop-
ment. 
Wortmannin and GSK690693 combination treatment significantly decreased 
zebrafish embryo survival after 72 h at even lower wortmannin concentration imply-
ing a synergistic action of the two PI3K/Akt/mTOR inhibitors. Combined treatment 
with inhibitors of downstream part of the PI3K/Akt/mTOR pathway, GSK690693 and 
AZD2014, did not significantly affect the survival of the treated embryos. Wortmannin + 
GSK690693 and GSK690693 + AZD2014 co-treatments produced morphological 
malformations not present in single treatments (hemagglutination and yolk sac mal-
formation) which further implies the synergistic action between these inhibitors.
Tipifrnib is a Ras pathway inhibitor approved by USFDA for the treatment of 
elderly acute leukemia, and is in phase II clinical trials for several other types of 
cancer [3]. In our study, treatment with tipifarnib affected zebrafish embryo morphol-
ogy as well as survival and development of sea urchin embryos, displaying higher 
toxicity on normal embryonic cells, compared to AZD2014 and GSK690693. 
Tipifarnib has been shown to effectively arrests cell growth in micro molar concentra-
tions (IC50 values ranging from 2 to 8 µM) [27]. Meanwhile it was very toxic to sea 
urchin embryos and caused zebrafish embryo malformations, we have shown that 
tipifarnib has prominent effect on normal proliferating cells.
CONCLUSIONS
In the search for new anticancer drugs, the main focus is placed on finding com-
pounds with substantial capacity to inhibit the cancer cell growth, particularly in 
resistant cancers, while exhibiting negligible effects on normal cells during the course 
of chemotherapy. We found that AZD2014 had no major effects on fast proliferating 
normal cells of zebrafish embryos in concentrations that induced substantial toxicity 
in cancer cells. Treatment with AZD2014 also caused the least prominent effects on 
sea urchin embryo development compared to other investigated inhibitors which tar-
get signaling pathways involved in regulating cell survival and proliferation.
Although further investigations are needed, the significant toxicity of AZD2014 in 
human cancer cells, its capacity to sensitize resistant cancers, lower antiproliferative 
activity against human normal cell lines as well as fast proliferating embryonic cells 
could make this agent a promising candidate for anticancer therapy.
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